• Syringin Natural Product: Applied Workflows in Bioactive Scr

  2026-06-13

  Syringin, a high-purity natural product from APExBIO, is redefining bioactive compound screening and apoptosis research through its unique ability to modulate EGFR/PI3K/Akt pathways and sensitize RCC cells to sunitinib. This article distills cutting-edge protocols, troubleshooting guidance, and comparative insights to help researchers harness Syringin’s full potential in experimental oncology.

• Deferiprone in Cancer Biology: Protocols, Innovation, and Tr

  2026-06-12

  Deferiprone (3-hydroxy-1,2-dimethylpyridin-4-one) stands out as a precision tool for dissecting iron-dependent signaling, apoptosis induction, and cytoprotection workflows in cancer and metabolic models. This deep-dive integrates reference-driven insights and actionable protocols, ensuring robust, reproducible research outcomes.

• Latrunculin A: Applied Protocols for Actin Cytoskeleton Disr

  2026-06-12

  Latrunculin A, a potent reversible inhibitor of actin assembly, empowers researchers to dissect cytoskeletal function with precision. Discover robust workflows, troubleshooting strategies, and the latest insights from host-pathogen interactome studies that set APExBIO’s Latrunculin A apart for cell morphology and motility research.

• Streptavidin-Cy3: Illuminating NPC Metastasis via Super-Enha

  2026-06-11

  This thought-leadership article explores how Streptavidin-Cy3 empowers translational researchers to dissect the molecular mechanisms driving nasopharyngeal carcinoma (NPC) metastasis. Integrating mechanistic insights from recent studies on carcinogen-induced super-enhancer RNAs with actionable protocol guidance, the article offers a strategic roadmap for leveraging advanced fluorescent biotin detection in oncology research. It critically differentiates itself from standard product overviews by combining evidence-based recommendations, workflow optimization for immunohistochemistry and immunofluorescence, and a forward-looking outlook on clinical translation.

• Methylprednisolone in Experimental Osteonecrosis: Mechanisti

  2026-06-11

  Explore the scientific depth of methylprednisolone, a synthetic glucocorticoid receptor agonist, in advanced inflammation and bone disease models. This article provides practical assay insights and uniquely contextualizes recent in vivo evidence for translational research.

• AO/PI Double Staining: Strategic Insights for Translational

  2026-06-10

  This article provides mechanistic and strategic guidance for translational researchers using the AO/PI Double Staining Kit. Integrating cutting-edge cell biology and clinical diagnostics, it explores how dual Acridine Orange and Propidium Iodide staining enables precise cell fate analysis, supports rare cell profiling, and advances cancer subtyping workflows. Drawing on recent innovations and competitive landscape analysis, this thought-leadership piece delivers actionable recommendations, protocol parameters, and a forward-looking vision for high-impact translational research.

• Synergistic Suppression of Pancreatic Tumors via CDK4/6 and

  2026-06-10

  Gu et al. demonstrate that combined inhibition of CDK4/6 and BET proteins yields a synergistic suppression of pancreatic ductal adenocarcinoma (PDAC) growth and epithelial-to-mesenchymal transition (EMT) by targeting the GSK3β-mediated Wnt/β-catenin pathway. This mechanistic insight informs future combinatorial strategies for overcoming tumor proliferation and metastasis in PDAC.

• Reliable Tag Cleavage with PreScission Protease (PSP) in Pro

  2026-06-09

  This article addresses real-world challenges in protein purification and fusion tag removal, highlighting how PreScission Protease (PSP) (SKU K1101) delivers reproducible and specific cleavage solutions. By exploring experimental design, optimization, and vendor selection, it positions PSP as a trusted tool for biomedical researchers seeking high-fidelity results.

• BIBP 3226 trifluoroacetate: Mechanistic Insights for NPY/NPF

  2026-06-09

  BIBP 3226 trifluoroacetate is a high-affinity non-peptide antagonist used to dissect NPY Y1 and NPFF receptor pathways. It enables precise investigation of neuropeptide signaling in anxiety, analgesia, and cardiovascular research. Evidence shows its utility in blocking NPY Y1-mediated arrhythmogenic signaling with nanomolar potency.

• Lopinavir (ABT-378): Defining Selectivity and Serum Resilien

  2026-06-08

  Explore how Lopinavir (ABT-378) uniquely combines picomolar HIV protease inhibition and serum resilience to drive next-generation HIV and cross-viral research. This article reveals advanced insights into assay design, resistance management, and practical learnings from the latest cross-domain antiviral screening.

• Rotigotine Hydrochloride for Dopaminergic Signaling Research

  2026-06-08

  Rotigotine hydrochloride, a potent dopamine D2/D3 receptor agonist, enables high-fidelity modeling of Parkinson’s disease and related non-motor symptoms such as overactive bladder. This article delivers actionable protocols, troubleshooting strategies, and practical insights stemming from recent experimental advances and the unique profile of APExBIO’s Rotigotine hydrochloride.

• Super-Enhancer RNA Drives Metastasis in Nasopharyngeal Carci

  2026-06-07

  This study uncovers how carcinogen-induced super-enhancer RNA (seRNA-NPCm) promotes metastasis in nasopharyngeal carcinoma (NPC) by orchestrating the NPM1/c-Myc/NDRG1 axis. The findings provide mechanistic insights and highlight new targets for understanding and potentially controlling NPC progression.

• FDA-Approved Drugs Identified as MERS-CoV Inhibitors in Cell

  2026-06-06

  de Wilde et al. conducted a high-content screen of 348 FDA-approved compounds and identified four small molecules, including Lopinavir (ABT-378), that inhibit MERS-CoV replication in cell culture. Their findings highlight the cross-viral potential of repurposed protease inhibitors in the context of emerging coronavirus threats, offering valuable data for antiviral research and translational studies.

• Technical Guide: FITC-Concanavalin A (ConA) Conjugate Use

  2026-06-05

  FITC-Concanavalin A (ConA) Conjugate enables targeted, fluorescence-based detection of α-D-glucose and α-D-mannose residues on cell surfaces. The product should be used for immunofluorescence staining and flow cytometry in glycobiology workflows, and is unsuitable for non-carbohydrate-binding applications or protocols requiring stability beyond its specified shelf life.

• MAPK10 Regulates NSCLC Metastasis via KRT16 Phosphorylation-

  2026-06-05

  This study reveals that mitogen-activated protein kinase 10 (MAPK10) suppresses non-small cell lung cancer (NSCLC) metastasis by promoting the phosphorylation-dependent ubiquitination and degradation of keratin 16 (KRT16). The findings highlight the MAPK10/KRT16/RNF213 axis as a novel therapeutic target and prognostic biomarker for NSCLC, with direct implications for developing more effective anti-metastatic strategies.

16208 records 1/1081 page Next 12345 下5页 Last page